Schering-Plough
3Q Revenues: $2.8 billion (+9%)
3Q Earnings: $750 million (+142%)
YTD Revenues: $9.0 billion (+13%)
YTD Earnings: $1.9 billion (+97%)
Comments: Revenues do not reflect sales of Vytorin and Zetia, which are accounted as "equity income from a joint venture". SP's share of that income was $639 million in 3Q (+27%) and $1.8 billion YTD (+34%). Global pharma sales rose 10% to $2.3 billion in 3Q07, driven by Remicade ($426 million / +34%), Nasonex ($242 million / +10%), and Temodar ($215 million / +20%).
Magazine
